Tividenofusp alfa is a novel central nervous system-penetrant enzyme replacement therapy designed to address the neurological manifestations of MPS II by delivering IDS into the brain and body.

The Food and Drug Administration (FDA) has approved Ekterly ® (sebetralstat) for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.